NIH: In People With HIV, Treating Precancerous Anal Lesions Cuts Risk of Anal Cancer by More Than Half
June 16, 2022
June 16, 2022
WASHINGTON, June 16 (TNSjou) -- The U.S. Department of Health and Human Services' National Institutes of Health issued the following news release:
A large clinical trial of people living with HIV has found that treating anal precancerous growths known as high-grade squamous intraepithelial lesions, or HSIL, reduces the chance that anal cancer will develop by more than half.
Results from the Anal Cancer/HSIL Outcomes Research (ANCHOR) study were published June 16 in . . .
A large clinical trial of people living with HIV has found that treating anal precancerous growths known as high-grade squamous intraepithelial lesions, or HSIL, reduces the chance that anal cancer will develop by more than half.
Results from the Anal Cancer/HSIL Outcomes Research (ANCHOR) study were published June 16 in . . .